- Home
- FRGE vs CRBP Comparison
FRGE vs CRBP Comparison
Compare FRGE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRGE
- CRBP
- Stock Information
- Founded
- FRGE 2014
- CRBP 2009
- Country
- FRGE United States
- CRBP United States
- Employees
- FRGE N/A
- CRBP 19
- Industry
- FRGE Computer Software: Prepackaged Software
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FRGE Technology
- CRBP Health Care
- Exchange
- FRGE Nasdaq
- CRBP Nasdaq
- Market Cap
- FRGE 196.1M
- CRBP 158.3M
- IPO Year
- FRGE N/A
- CRBP N/A
- Fundamental
- Price
- FRGE $0.94
- CRBP $13.00
- Analyst Decision
- FRGE Strong Buy
- CRBP Strong Buy
- Analyst Count
- FRGE 3
- CRBP 8
- Target Price
- FRGE $4.50
- CRBP $62.00
- AVG Volume (30 Days)
- FRGE 710.3K
- CRBP 313.3K
- Earning Date
- FRGE 11-06-2024
- CRBP 11-07-2024
- Dividend Yield
- FRGE N/A
- CRBP N/A
- EPS Growth
- FRGE N/A
- CRBP N/A
- EPS
- FRGE N/A
- CRBP N/A
- Revenue
- FRGE $79,799,000.00
- CRBP N/A
- Revenue This Year
- FRGE $19.18
- CRBP N/A
- Revenue Next Year
- FRGE $34.32
- CRBP N/A
- P/E Ratio
- FRGE N/A
- CRBP N/A
- Revenue Growth
- FRGE 18.08
- CRBP N/A
- 52 Week Low
- FRGE $0.80
- CRBP $5.25
- 52 Week High
- FRGE $4.02
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- FRGE 39.86
- CRBP 25.10
- Support Level
- FRGE $0.90
- CRBP $12.90
- Resistance Level
- FRGE $1.25
- CRBP $16.21
- Average True Range (ATR)
- FRGE 0.09
- CRBP 0.95
- MACD
- FRGE -0.01
- CRBP -0.16
- Stochastic Oscillator
- FRGE 2.14
- CRBP 1.69
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The Company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.